Clinical Trial Update: One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial of an oral ziprasidone regimen in bipolar disorder patients with metabolic syndrome was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ziprasidone (ziprasidone)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Bipolar Disorder | Phase 3 | Status: TERMINATED | Results posted: 2012-07-09